Boomerang

Boomerang Medical is a private, women-led clinical-stage bioelectronic medicine company developing neuromodulation therapies for autoimmune disease, with an initial focus on inflammatory bowel disease. Its lead program uses sacral nerve stimulation to reduce inflammation and improve symptoms in ulcerative colitis and Crohn's disease. The company has received FDA Breakthrough Device Designation for its IBD-focused technology and has advanced from an early feasibility study into a pivotal ulcerative colitis trial. Boomerang Medical is headquartered in Mountain View, California and is backed by venture investors including Arboretum Ventures and Hatteras Venture Partners.